Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
04:30am, Thursday, 13'th Feb 2025
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has be
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
08:15am, Wednesday, 12'th Feb 2025
The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are permit
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
09:40am, Thursday, 06'th Feb 2025
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company"
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
09:10am, Wednesday, 05'th Feb 2025
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
03:34am, Wednesday, 05'th Feb 2025
Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
02:48pm, Tuesday, 04'th Feb 2025
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.
Global Partners: The Preferred Units Are Better
04:42pm, Sunday, 02'nd Feb 2025
Global Partners LP has substantial leverage and arguably unsustainable growth prospects. The preferred units offer a higher yield of 9% and lower risk compared to the common units. The company's high
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
06:36am, Sunday, 02'nd Feb 2025
Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of
New study reveals why patients stop taking GLP-1 obesity drugs
06:05pm, Friday, 31'st Jan 2025
Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why GLP-1 users stop taking the drug.
Global Partners (GLP) Soars 6.8%: Is Further Upside Left in the Stock?
06:01am, Friday, 31'st Jan 2025
Global Partners (GLP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
06:56am, Thursday, 30'th Jan 2025
Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the a
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
09:15am, Wednesday, 29'th Jan 2025
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for
Global Partners Declares Fourth-Quarter 2024 Cash Distribution of $0.7400 on Common Units
08:30am, Wednesday, 29'th Jan 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has declared a cash distribut
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been rep
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
07:45am, Saturday, 25'th Jan 2025
For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management. While Novo N
